English Funding Nod For Lilly’s Diabetes GLP-1 Mounjaro, Roche’s Cancer MAb Columvi
Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.
You may also be interested in...
The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.
Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term.
Data provided to the Pink Sheet under freedom of information requests show the scale of patient access that has been delivered under the UK’s scheme for early access to products that have yet to receive a marketing authorization.